Trademark: 88028436
Word
NOVELLUS
Status
Registered
Status Code
700
Status Date
Tuesday, March 10, 2020
Serial Number
88028436
Registration Number
6008685
Registration Date
Tuesday, March 10, 2020
Mark Type
4000
Filing Date
Friday, July 6, 2018
Published for Opposition
Tuesday, June 18, 2019

Trademark Owner History
Factor Bioscience LLC - Original Registrant

Classifications
1 Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering
5 Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease
9 Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments
42 Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing
The wording "NOVELLUS" has no meaning in a foreign language.

Trademark Events
Mar 10, 2020
Registered-Principal Register
Feb 7, 2020
Notice Of Acceptance Of Statement Of Use E-Mailed
Feb 6, 2020
Allowed Principal Register - Sou Accepted
Dec 29, 2019
Statement Of Use Processing Complete
Dec 18, 2019
Use Amendment Filed
Dec 29, 2019
Case Assigned To Intent To Use Paralegal
Dec 18, 2019
Teas Statement Of Use Received
Aug 13, 2019
Noa E-Mailed - Sou Required From Applicant
Jun 18, 2019
Official Gazette Publication Confirmation E-Mailed
Jun 18, 2019
Published For Opposition
May 29, 2019
Notification Of Notice Of Publication E-Mailed
May 10, 2019
Approved For Pub - Principal Register
May 10, 2019
Examiner's Amendment Entered
May 10, 2019
Notification Of Examiners Amendment E-Mailed
May 10, 2019
Examiners Amendment E-Mailed
May 10, 2019
Examiners Amendment -Written
May 9, 2019
Examiner's Amendment Entered
May 9, 2019
Notification Of Examiners Amendment E-Mailed
May 9, 2019
Examiners Amendment E-Mailed
May 9, 2019
Examiners Amendment -Written
Apr 10, 2019
Notification Of Final Refusal Emailed
Apr 10, 2019
Final Refusal E-Mailed
Apr 10, 2019
Final Refusal Written
Feb 19, 2019
Teas/Email Correspondence Entered
Feb 19, 2019
Correspondence Received In Law Office
Feb 18, 2019
Assigned To Lie
Feb 12, 2019
Teas Response To Office Action Received
Oct 27, 2018
Notification Of Non-Final Action E-Mailed
Oct 27, 2018
Non-Final Action E-Mailed
Oct 27, 2018
Non-Final Action Written
Oct 25, 2018
Assigned To Examiner
Jul 12, 2018
New Application Office Supplied Data Entered In Tram
Jul 10, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24